Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis

Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis

Backgrounds: Immune checkpoint inhibitors (ICIs) are considered cornerstones of oncology treatment with durable anti-tumor efficacy, but the increasing use of ICIs is associated with the risk of developing immune-related adverse events (irAEs). Although ICI-associated pancreatic adverse events (AEs)...

Full description

Bibliographic Details
Main Authors: Yue Zhang, Yisheng Fang, Jianhua Wu, Genjie Huang, Jianping Bin, Yulin Liao, Min Shi, Wangjun Liao, Na Huang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Pharmacology
Subjects:
immune checkpoint inhibitors
PD-1/PD-L1
CTLA-4
combination therapy
pancreatic adverse events
pancreatitis
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.817662/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.817662/full

Similar Items